The decision to begin fertility treatment is one of the most emotionally significant choices a couple or individual can make. By the time most patients reach the stage of ovarian stimulation treatment, they have already spent months or years navigating the uncertainty of infertility, the emotional weight of failed attempts, and the complex information landscape of assisted reproduction.
What happens at the ovarian stimulation stage is not a standardised procedure that produces the same result regardless of who performs it. The protocol chosen, how closely the response is monitored, how the dose is adjusted in real time, and how the risk of complications is managed all depend on the experience and clinical judgement of the specialist involved.
Choosing the right fertility specialist for ovarian stimulation treatment in Chennai is not simply a logistical decision. It is a clinical one that shapes the entire treatment cycle.
What Is Ovarian Stimulation Treatment?
Ovarian stimulation treatment is the process of using hormonal medications to encourage the ovaries to produce multiple mature follicles in a single cycle, rather than the single egg a woman's body would naturally produce. The goal is to retrieve multiple eggs for fertilisation, increasing the number of viable embryos available for transfer and improving the overall probability of a successful pregnancy from a single treatment cycle. In a natural cycle, a complex hormonal interplay results in the development of one dominant follicle and the suppression of all others. Ovarian stimulation overrides this process, using injectable gonadotrophins containing follicle-stimulating hormone (FSH), with or without luteinising hormone (LH), to stimulate the simultaneous development of multiple follicles to maturation.
When Ovarian Stimulation Is Used
Ovarian stimulation treatment is a central component of in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI), where the goal is to retrieve and fertilise multiple eggs in a single cycle. It is also used in a milder form in intrauterine insemination (IUI), where the aim is to produce one or two mature follicles to time insemination more precisely than in a natural cycle.
Beyond fertility treatment, ovarian stimulation is used in elective egg freezing and in egg donation cycles. The ESHRE 2025 guideline update specifically expanded its coverage of fertility preservation, including elective oocyte cryopreservation and oocyte donation, reflecting the growing clinical importance of these applications.
Ovarian Stimulation Protocols What the 2025 Guidelines Say
The European Society of Human Reproduction and Embryology (ESHRE) published its updated ovarian stimulation guideline in 2025, the most comprehensive revision since 2019, providing 121 recommendations covering the full range of stimulation scenarios, patient profiles, and clinical decision points. Understanding the direction of current evidence helps patients ask better questions of their fertility specialist and understand why a particular protocol has been recommended for them.
The central theme of the 2025 guideline is individualisation. Protocol selection based on a woman's individual profile, her ovarian reserve (assessed by AMH and antral follicle count), her age, her body weight, and any prior stimulation history, produces better outcomes than applying a standard protocol uniformly.
The GnRH Antagonist Protocol
The GnRH antagonist protocol has become the most widely used ovarian stimulation protocol in contemporary fertility practice, and the 2025 ESHRE guideline reflects and supports this trend. In the antagonist protocol, stimulation with gonadotrophins begins early in the menstrual cycle, and a GnRH antagonist is added around day five or six of stimulation to prevent premature ovulation before the eggs are ready for retrieval.
The antagonist protocol offers several advantages over the older long agonist protocol. It requires no prolonged downregulation phase before stimulation begins, shortening the overall treatment timeline. It allows more flexible monitoring and dose adjustment throughout stimulation. And critically, in the event of an excessive ovarian response in high-risk patients such as those with PCOS, it allows the use of a GnRH agonist rather than an hCG trigger to induce final egg maturation, dramatically reducing the risk of ovarian hyperstimulation syndrome.
The Long GnRH Agonist Protocol
The long agonist protocol, where a GnRH agonist is started in the luteal phase of the preceding cycle to downregulate pituitary function before stimulation begins, remains in use for certain patient profiles, particularly where a high degree of LH suppression and controlled stimulation onset is clinically preferred. In patients with a history of premature LH surges, endometriosis, or specific clinical scenarios, the long protocol remains a clinically justified option.
For women with poor ovarian response, including those classified under the POSEIDON criteria as low prognosis patients, protocol selection is particularly important. The 2025 guideline provides specific updated recommendations for low responders, including the use of LH supplementation, adjuvant growth hormone, and modified stimulation approaches designed to optimise the response from a limited ovarian reserve.
Mild Stimulation and Natural Cycle IVF
For certain patients, including those with very poor ovarian reserve, those who have had prior excessive responses, older women, and those who prefer a less intensive treatment approach, mild stimulation protocols using lower doses of gonadotrophins or oral agents such as clomiphene or letrozole in combination with low-dose injectable FSH, represent a clinically appropriate alternative.
Natural cycle IVF, without any stimulation medication, is occasionally appropriate for specific clinical situations where the patient produces a reliable natural cycle and where the physical or emotional demands of full stimulation are not appropriate. These approaches produce fewer eggs per cycle and are therefore used when a modest number of high-quality eggs is the goal, rather than a large cohort of eggs.
The Monitoring Process During Ovarian Stimulation
Ovarian stimulation treatment is not administered and then waited on. It requires close, structured monitoring throughout the stimulation phase, because the ovarian response to gonadotrophins varies between patients and even between cycles in the same patient, and the dose must be adjusted in real time based on what the monitoring reveals.
What Monitoring Involves and Why It Matters
Monitoring during ovarian stimulation involves two parallel streams of information: transvaginal ultrasound to count and measure developing follicles, and blood hormone measurements to track oestradiol and LH levels throughout the stimulation phase.
Ultrasound monitoring, typically performed every one to three days from around day six of stimulation onward, tracks the number of follicles developing and their size. Egg retrieval is timed when the leading follicles reach approximately 17 to 18 mm in diameter, a size associated with mature egg development. The number and distribution of follicles also guides the dose adjustment decisions made throughout the stimulation phase.
Hormone monitoring provides complementary information. Rising oestradiol levels confirm that the follicles are producing hormones and developing normally. An LH measurement identifies any risk of premature ovulation that might require an adjustment in protocol. In patients at risk of an excessive response, oestradiol trends guide decisions about triggering earlier or coasting the stimulation to reduce OHSS risk.
The quality and frequency of monitoring during ovarian stimulation treatment is one of the most important factors distinguishing centres that produce consistent results from those that do not. Adequate monitoring allows the dose to be optimised for each individual patient's response, the timing of the trigger to be precise, and the risk of OHSS to be actively managed rather than simply responded to after it has developed.
Ovarian Hyperstimulation Syndrome The Primary Risk of Stimulation Treatment
Ovarian hyperstimulation syndrome (OHSS) is the most significant complication of ovarian stimulation treatment, occurring when the ovaries respond excessively to gonadotrophin stimulation, producing a large number of follicles and releasing vascular mediators that cause fluid to shift from the bloodstream into body cavities. Mild OHSS, characterised by abdominal bloating, mild discomfort, and some nausea, is relatively common and resolves without specific treatment. Moderate OHSS involves more pronounced abdominal swelling and discomfort, and may require closer monitoring. Severe OHSS, involving significant fluid accumulation in the abdomen and chest, reduced urine output, and in rare cases blood clotting complications, requires hospitalisation and active management.
How OHSS Risk Is Managed in Current Practice
The most important advance in OHSS prevention has been the widespread adoption of the GnRH agonist trigger in high-risk patients in antagonist cycles. When an agonist rather than hCG is used to trigger final egg maturation, the sustained LH-like effect of hCG on the corpora lutea is avoided, dramatically reducing the ovarian response in the days following egg retrieval.
The 2025 ESHRE guideline provides specific updated recommendations on OHSS prevention, including individualised gonadotrophin dosing based on AMH and antral follicle count, threshold criteria for applying a freeze-all strategy (where no fresh embryo transfer is performed in a cycle with an excessive ovarian response, and all embryos are frozen for transfer in a subsequent cycle), and the use of dopamine agonists such as cabergoline as pharmacological OHSS prevention adjuncts in high-risk patients.
For patients with PCOS, who are at the highest risk of excessive ovarian response, the antagonist protocol with GnRH agonist trigger and a planned freeze-all strategy is the current evidence-based approach that minimises OHSS risk while preserving the embryos produced for subsequent frozen embryo transfer.
What Patients With Specific Profiles Need to Know
Not every patient's ovarian stimulation treatment looks the same. Understanding how the approach differs across the most common clinical profiles helps patients engage more meaningfully with their treatment plan and understand why their specialist has made the specific recommendations they have.
Patients With PCOS
Women with PCOS are among the most complex to manage during ovarian stimulation, because they represent both a high responder risk (due to their high antral follicle count and ovarian volume) and a group with specific hormonal patterns that affect stimulation response. The ESHRE 2025 guideline specifically addresses PCOS stimulation, recommending lower starting gonadotrophin doses to avoid excessive response, the antagonist protocol to allow GnRH agonist triggering when needed, and a freeze-all strategy when any risk of moderate or severe OHSS is present.
Mild stimulation with oral agents or low-dose FSH is an appropriate alternative for some women with PCOS who have responded excessively in prior cycles. The clinical goal is to find the dose that produces a modest but adequate cohort of eggs, typically eight to fifteen follicles, without triggering the cascade that leads to OHSS.
Poor Ovarian Responders
Women with diminished ovarian reserve, whether from age, prior ovarian surgery, or other causes, present the opposite challenge from PCOS patients. Here, the goal is to extract the maximum possible response from a limited follicle pool, while ensuring the eggs produced are of the best possible quality.
Current evidence supports higher starting gonadotrophin doses in poor responders, with the possible addition of LH supplementation through products containing both FSH and LH activity. The 2025 ESHRE guideline includes specific new recommendations on adjuvant treatments for low responders, including growth hormone supplementation, which has shown benefit in specific low-prognosis patient groups in recent randomised trial data.
Women Over 35 and Patients With Previous Failed Cycles
Advancing maternal age reduces both the quantity and chromosomal quality of eggs available for retrieval. For women over 35, the stimulation protocol must balance the goal of retrieving adequate egg numbers against the reality that a higher proportion of the eggs produced will have chromosomal abnormalities. Preimplantation genetic testing for aneuploidy (PGT-A) is increasingly used in combination with ovarian stimulation in this group, allowing the transfer of chromosomally normal embryos only and improving the probability of a successful implantation from a limited embryo cohort.
For patients who have had previous failed cycles, a thorough review of the prior stimulation response, specifically how many follicles developed, what the peak oestradiol level was, how many mature eggs were retrieved, and how many progressed to viable embryos, is essential before the next protocol is selected. Protocol change between cycles should be evidence-driven rather than arbitrary.
Meet Dr Asma Humayun Fertility Specialist at Humayun Hospital, Chennai
Choosing the right specialist for ovarian stimulation treatment in Chennai involves assessing qualifications, subspecialty training, clinical experience, and the breadth of fertility procedures the specialist manages independently. Dr Asma Humayun meets this standard comprehensively.
Dr Asma Humayun is a Gynaecologist and Obstetrician with over 15 years of clinical experience, practising at Humayun Hospital, Chennai. Her qualifications span both the clinical and academic spectrum of reproductive medicine, with a foundation in rigorous postgraduate training followed by internationally recognised subspecialty credentials.
Qualifications and Subspecialty Training
Dr. Asma Humayun is an internationally trained Gynecologist, Obstetrician, and Fertility Specialist with over 13 years of clinical expertise.
-
Foundational Education: Completed her MBBS from Rajiv Gandhi University of Health Sciences (2006) and her DGO from Sri Ramachandra University, Chennai (2011).
-
Advanced Fertility & ART: Holds a Fellowship in Assisted Reproductive Techniques (F.ART), mastering the clinical execution of IUI, IVF, ICSI, and complex ovarian stimulation protocols.
-
Minimally Invasive Surgery: Earned a Fellowship in Minimal Access Surgery (F.MAS), specializing in advanced laparoscopy and hysteroscopy for crucial pre-fertility corrections like endometriosis tissue removal.
-
Global Credentials: Holds a Diploma in Reproductive Medicine from Germany alongside a prestigious Membership of the Royal College of Obstetricians and Gynaecologists (MRCOG, UK), validating her practice under rigorous international clinical standards.
Clinical Scope & Special Interests
Dr. Asma Humayun provides comprehensive reproductive medicine and fertility care, offering integrated medical and surgical interventions throughout the treatment journey.
-
Ovulatory & Endocrine Disorders: Specializes in managing PCOS, PCOD, irregular cycles, and anovulation (lack of ovulation) to optimize ovarian stimulation protocols.
-
Pre-Fertility Structural Corrections: Treats uterine fibroids, endometrial polyps, and ovarian cysts that must be resolved before initiating assisted reproductive technologies (ART).
-
Advanced ART Services: Directs complete fertility treatments including Intrauterine Insemination (IUI), In Vitro Fertilization (IVF), and Intracytoplasmic Sperm Injection (ICSI).
-
Integrated Surgical Care: Expertly performs diagnostic and operative laparoscopy and hysteroscopy. By handling pelvic and uterine factor corrections in-house, she eliminates the need for external surgical referrals and streamlines the timeline to embryo transfer.
What to Look for When Choosing a Fertility Specialist in Chennai
The number of fertility clinics and specialists in Chennai has expanded considerably, which is broadly positive for patients but also creates the challenge of differentiating between providers on dimensions beyond location and cost.
Several specific criteria are worth assessing when choosing a specialist for ovarian stimulation treatment in Chennai.
The Criteria That Actually Differentiate Specialists
-
Subspecialty qualifications in reproductive medicine: A gynaecologist with a general DGO or MD brings obstetric and gynaecological training, but fertility treatment, particularly ovarian stimulation, is a subspecialty that benefits from additional specific training. An F.ART or international reproductive medicine diploma indicates that the specialist has pursued focused postgraduate education in ART beyond the generalist qualification.
-
Experience with diverse stimulation profiles: A specialist who sees only straightforward stimulation cases does not develop the clinical judgement needed to manage poor responders, PCOS high-responders, or patients who have failed multiple prior cycles. Asking directly about the volume and variety of stimulation cases managed gives a better sense of this.
-
Monitoring infrastructure: Quality ovarian stimulation treatment requires frequent, high-resolution transvaginal ultrasound and timely hormone blood tests. Asking how monitoring is conducted, how frequently, and who interprets the results and makes dose adjustments, clarifies whether the monitoring standard matches what the current evidence recommends.
-
Approach to OHSS prevention: A specialist who routinely uses a freeze-all strategy in high-risk patients, who adjusts the trigger based on ovarian response, and who uses the GnRH agonist trigger in antagonist cycles when indicated is practising in accordance with 2025 ESHRE guideline recommendations. A specialist who triggers all patients with hCG regardless of response profile is not.
-
Transparency about outcomes: A reputable fertility specialist should be willing to discuss their practice's outcomes for patients with a similar profile to the patient enquiring, including the proportion of cycles that reach egg retrieval, the average number of mature eggs retrieved, fertilisation rates, and clinical pregnancy rates per transfer.
The Conversation to Have Before Starting Ovarian Stimulation Treatment
The consultation before an ovarian stimulation cycle is the most important clinical interaction in the entire treatment process. It is the point at which the specialist reviews the complete fertility workup, explains the proposed protocol and why it has been chosen for this specific patient, and sets clear expectations for the monitoring schedule and the realistic range of outcomes.
Questions Worth Asking Your Fertility Specialist
What protocol are you recommending for me and why? A clear, individualised answer to this question, referencing the patient's AMH level, antral follicle count, prior response history, and any specific risk factors, demonstrates that the specialist has engaged with the individual profile rather than defaulting to a standard approach.
What is my risk of OHSS and how will it be managed if my response is excessive? Understanding the specific OHSS prevention plan, including whether a freeze-all strategy will be applied if the response is very high, clarifies what will happen in the event of an unexpected outcome.
How often will I be monitored during stimulation and who makes dose adjustment decisions? The answer reveals how closely the stimulation is supervised and at what level of clinical seniority real-time decisions are made.
What happens if fewer eggs are retrieved than expected? Understanding the plan for a suboptimal response, including whether the cycle will proceed to retrieval with fewer follicles or whether a cycle cancellation threshold exists, prepares the patient for the full range of possible outcomes.
How many cycles of ovarian stimulation should I plan for? The cumulative probability of pregnancy over multiple cycles is often significantly higher than the per-cycle probability, and a realistic discussion about the likely number of cycles gives patients a more complete picture of what they are committing to.
Ovarian Stimulation Treatment at Humayun Hospital, Chennai
At Humayun Hospital, T Nagar, Chennai, ovarian stimulation treatment is approached with the clinical depth and individualisation that current evidence demands.
Dr Asma Humayun brings her ART fellowship training, her reproductive medicine diploma, and over 15 years of clinical experience across the full spectrum of fertility conditions to every stimulation cycle she manages. Her practice is informed by the same evidence base that underpins the 2025 ESHRE guideline update, including individualized protocol selection based on ovarian reserve assessment, the use of GnRH antagonist protocols as the default approach for most patients, specific adaptations for PCOS and poor responder profiles, and structured OHSS prevention for high-risk individuals.
For patients in Chennai who are beginning fertility treatment for the first time, seeking a second opinion after a prior cycle that did not go as expected, or looking for a specialist who combines international training with local clinical experience, Humayun Hospital offers an accessible and experienced option in the centre of T Nagar. Chat with our medical care assistant for quick guidance and support.
